Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nonprofit Groups Work To Bring Device Companies Together For Supplier Accreditation

This article was originally published in The Silver Sheet

Executive Summary

As the device industry looks to beef up supply chain quality, a pair of nonprofit organizations – Rx-360 and the Performance Review Institute – is offering manufacturers a chance to take part in programs that would allow for greater control over vendors. PRI’s initiative would focus its audits on vendors that provide manufacturers with five critical process-specific activities, while Rx-360’s program will dispatch auditors to review a supplier’s overall quality management system. In theory, firms that use either program will save resources because they could spend less time and money overseeing suppliers. In turn, vendors would welcome fewer manufacturer audits. But there is one lingering question: Should PRI and Rx-360 join forces? Former FDAer Steven Niedelman believes it could happen. “If a manufacturer participates in both programs, then they’ll have supplier control completely locked down,” he says.

You may also be interested in...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts